Aditxt to acquire AiPharma in all-stock deal valued at ~44.7M shares plus $500K cash

Aditxt, Inc.

Initial closing by Jan 31, 2022 for 9.5% of AiPharma: 4.8M shares + $250K cash.
Secondary closing for remaining 90.5% subject to shareholder and Nasdaq approval: 39.9M shares + $250K cash.
AiPharma holds exclusive rights to Avigan (favipiravir) for COVID-19; Phase 3 trial missed primary endpoint.
Two board members, Lauren Chung and Laura Anthony, resigned effective Dec 31, 2021; no disagreement cited.
AiPharma has strategic alliance with Appili Therapeutics (TSX:APLI) and plans new global clinical trial for Avigan.

item 1.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Laura Anthony

Director

ADTX · Aditxt, Inc.

Effective: 2021-12-31
Filed: December 28, 2021, 6:59 PM ET

On December 26, 2021, Laura Anthony notified the Company that effective December 31, 2021, she is resigning from the Company’s Board of Directors.

Departed

Lauren Chung

Director

ADTX · Aditxt, Inc.

Effective: 2021-12-31
Filed: December 28, 2021, 6:59 PM ET

On December 24, 2021, Lauren Chung notified the Company that effective December 31, 2021, she is resigning from the Company’s Board of Directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Laura Anthony resigned as Director at Aditxt, Inc..

Action: resigned
Role: Director

Exact text from the filing

On December 26, 2021, Laura Anthony notified the Company that effective December 31, 2021, she is resigning from the Company’s Board of Directors.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lauren Chung resigned as Director at Aditxt, Inc..

Action: resigned
Role: Director

Exact text from the filing

On December 24, 2021, Lauren Chung notified the Company that effective December 31, 2021, she is resigning from the Company’s Board of Directors.

View on SEC.gov

Aditxt, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-21-067652

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.